These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37958791)

  • 61. Cellular Immunotherapy in Lymphoma: Beyond CART Cells.
    Gaballa MR; Ramos CA
    Curr Treat Options Oncol; 2020 Feb; 21(3):21. PubMed ID: 32048071
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
    Ma SD; Xu X; Jones R; Delecluse HJ; Zumwalde NA; Sharma A; Gumperz JE; Kenney SC
    PLoS Pathog; 2016 May; 12(5):e1005642. PubMed ID: 27186886
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
    Ngo MC; Ando J; Leen AM; Ennamuri S; Lapteva N; Vera JF; Min-Venditti A; Mims MP; Heslop HE; Bollard CM; Gottschalk S; Rooney CM
    J Immunother; 2014 May; 37(4):193-203. PubMed ID: 24714353
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
    Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
    Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
    [No Abstract]   [Full Text] [Related]  

  • 66. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection.
    Zhang B; Zong Y; He J; Zhong B; Lin S
    Chin Med J (Engl); 2003 Jun; 116(6):913-7. PubMed ID: 12877806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
    Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
    J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
    Ma SD; Yu X; Mertz JE; Gumperz JE; Reinheim E; Zhou Y; Tang W; Burlingham WJ; Gulley ML; Kenney SC
    J Virol; 2012 Aug; 86(15):7976-87. PubMed ID: 22623780
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
    Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
    Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epstein-Barr Virus-Positive Lymphomas Exploit Ectonucleotidase Activity To Limit Immune Responses and Prevent Cell Death.
    Lange PT; Damania B
    mBio; 2023 Apr; 14(2):e0345922. PubMed ID: 36786572
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
    Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
    J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay.
    Calarota SA; Chiesa A; Zelini P; Comolli G; Minoli L; Baldanti F
    Immunology; 2013 Aug; 139(4):533-44. PubMed ID: 23560877
    [TBL] [Abstract][Full Text] [Related]  

  • 78. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
    Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.
    Yang D; Shao Q; Sun H; Mu X; Gao Y; Jiang R; Hou J; Yao K; Chen Y; Sun B
    Clin Dev Immunol; 2011; 2011():716926. PubMed ID: 21969838
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1.
    Yamamoto T; Nakamura Y; Kishimoto K; Takeuchi H; Shirakata M; Mitsuya T; Hirai K
    Virus Res; 1999 Dec; 65(1):43-55. PubMed ID: 10564752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.